Roche Presents Data at American Society of Hematology (ASH) Annual Meeting

TOKYO, December 12, 2022 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on data presentation regarding therapeutic antibodies created by Chugai, Hemlibra ® and crovalimab, at the American Society of Hematology (ASH) Annual Meeting. Please refer to the link below for details: Interim data from phase III study presented at ASH 2022 show Hemlibra achieved meaningful bleed control in infants from birth https://www.roche.com/media/releases/med-cor-2022-12-11b Roche’s subcutaneous crovalimab given every four weeks achieves disease control in people with PNH, a life-threatening blood condition https://www.roche.com/media/releases/med-cor-2022-12-11 Trademarks used or mentioned in this release are protected by laws.

The release as fetched from its publisher. chugai-pharm.co.jp ↗